CareDx, Inc (NASDAQ:CDNA) Given Consensus Recommendation of “Hold” by Brokerages

CareDx, Inc (NASDAQ:CDNA) has been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $29.60.

A number of research firms recently issued reports on CDNA. The Goldman Sachs Group increased their target price on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research note on Thursday, October 17th. BTIG Research cut their target price on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd.

Insider Buying and Selling at CareDx

In other CareDx news, Director Peter Maag sold 5,000 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the director now directly owns 330,024 shares of the company’s stock, valued at $8,250,600. This represents a 1.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.90% of the stock is owned by corporate insiders.

Institutional Trading of CareDx

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. bought a new stake in shares of CareDx in the third quarter worth $557,000. Lord Abbett & CO. LLC acquired a new position in CareDx during the 3rd quarter worth $10,873,000. Franklin Resources Inc. increased its position in shares of CareDx by 34.4% in the 3rd quarter. Franklin Resources Inc. now owns 59,474 shares of the company’s stock worth $1,862,000 after purchasing an additional 15,238 shares during the last quarter. Virtue Capital Management LLC acquired a new stake in shares of CareDx in the 3rd quarter valued at about $755,000. Finally, Geode Capital Management LLC lifted its position in shares of CareDx by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company’s stock worth $38,343,000 after purchasing an additional 32,141 shares during the last quarter.

CareDx Stock Down 1.5 %

Shares of CDNA opened at $23.63 on Monday. The firm has a market cap of $1.27 billion, a PE ratio of -8.75 and a beta of 1.86. The company’s fifty day moving average is $22.94 and its two-hundred day moving average is $24.12. CareDx has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The firm had revenue of $82.88 million during the quarter, compared to the consensus estimate of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm’s quarterly revenue was up 23.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.43) earnings per share. As a group, equities research analysts anticipate that CareDx will post -0.7 earnings per share for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.